Should not be administered to patients with a history of hepatic disease or serious blood disorder.
Should not be administered immediately before in conjunction with, or immediately after administering a MAO inhibitor. When it seems desirable to administer carbamazepine to a patient who has been receiving a MAO Inhibitor, there should be as long a drug-free interval as the clinical condition will allow. In no case should this be less than 14 days. The dosage of Apo-Carbamazepine should be low initially and increases very gradually.
Patients presenting atrio-ventricular heart block should not be given carbamazepine.
Because of similarity of chemical structure, carbamazepine should not be administered to patients with a known hypersensitivity to any of the tricyclic compounds such as amitriptyline, trimipramine, imipramine, or their analogue or metabolites.